#cdk46

First head-to-head comparison details the molecular profiles of CDK4/6 inhibitors — ScienceDaily

Every year, more than 250,000 women in the U.S. are diagnosed with breast cancer. When detected early, patients with the most common form — which tests positive for hormone receptors (HR+) and negative for the HER2 receptor — usually respond well to treatment. But for those in advanced stages, few treatment options existed until the recent emergence of a new class of drugs known as CDK4/6…